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AIM Renal denervation is an emerging technique for the treatment of patients with
drug-resistant hypertension. Long-term results using multi-electrode systems have
not been reported. We investigated the safety and efﬁcacy of the EnligHTN ablation
system developed by St. Jude Medical.
METHODS AND RESULTS The EnligHTN renal denervation system has 4 electrodes
attached on a basket mounted at the tip of the catheter. The basket is collapsed and
can be expanded via an external mechanism. The electrodes are then sequentially
activated to achieve the desired lesion pattern. The basket is then pulled back and
repositioned for a new set of lesions in order to optimize renal artery denervation.
The EnligHTN-I ﬁrst-in-human study was designed to assess the safety and efﬁcacy of
this multi-electrode ablation system in patients with drug-resistant hypertension. A
total of 46 patients (average age 6010yrs taking an average of 4.71.0 medications)
were enrolled in this study. Of these patients 33% were female, 98% were white, 20%
had Coronary Artery Disease, 59% had hyperlipidemia, 33% had type II Diabetes
Mellitus, and 30% had history of sleep apnea. Bilateral renal nerve ablation was
performed using a percutaneous femoral approach. On average 7.70.8 lesions were
created in the right renal artery and 7.41.4 in the left renal artery. The median
procedure time was 34 minutes.
Baseline average ofﬁce blood pressure was 176/96 mmHg and average 24 hr
ambulatory blood pressure was 150/83 mmHg. Average reductions (mmHg) of ofﬁce
blood pressure at 1, 3, 6, 12, 18 and 24 months were -28/10, -27/10, -26/10, -27/11, -24/
10 and -29/13 mmHg (p<0.0001) respectively. For the 24hr ambulatory blood pressure
reductions at 1, 3, 6, and 12 was -9/5, -10/5, -10/6, -7/4 and -13/7 mmHg (p<0.0001 for
1,3,6 and 24 P<0.0094 for 12 months) respectively. At 24 months 77% of patients were
responders (at least 10 mmHg reduction in systolic blood pressure) and 39% had
normalized blood pressure (<140 mmHg systolic blood pressure). The study utilized
an independent Clinical Events Committee to adjudicate all adverse events. Based on
their adjudication, there were 4 device/procedure related serious adverse events in 3
subjects reported to date which include: hypertensive renal disease progression,
symptomatic hypotension, worsening of pre-existing renal artery stenosis and new
stenotic lesion.
CONCLUSIONS We conclude that data demonstrates that the EnligHTN ablation
system continues to be safe and effective in the treatment of patients with drug-
resistant hypertension.VALVE & STRUCTURAL HEARTAORTIC VALVE
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BACKGROUND Transcatheter aortic valve replacement (TAVR) has being increasingly
offered in low and intermediate surgical risk patients with severe aortic stenosis (AS),
although the effectiveness of TAVR in this particular population has not beendemonstrated yet. This analysis aims to describe 1-year clinical outcomes of a large
series of propensity-matched patients at intermediate risk undergoing surgical aortic
valve replacement (SAVR) and transfemoral TAVR.
METHODS OBSERVANT is an observational prospective multicenter cohort study,
enrolling AS patients undergoing SAVR or TAVR. Propensity score method was
applied to select two groups with similar baseline characteristics. All outcomes were
adjudicated through a linkage with administrative databases. The primary end points
of the OBSERVANT study were death from any cause, and major adverse cardiac and
cerebrovascular events (MACCE) at 1 year. MACCE were deﬁned as the composite of
death from any cause, stroke, myocardial infarction, PCI and CABG. Prespeciﬁed
secondary end points included repeat hospitalization due to cardiac reasons and
acute heart failure have been analyzed.
RESULTS The unadjusted enrolled population (N¼7,618) comprises 5,707 SAVR pa-
tients and 1,911 TAVR patients. Matched population comprised a total of 1,300 pa-
tients (650 patients for each group). An intermediate risk population was selected
(mean logistic EuroSCORE 10.29.2% vs. 9.57.1%, SAVR vs. transfemoral TAVR;
p¼0.104). At 1-year, the rate of death from any cause was 13.6% in the surgical group
as compared with 13.8% in the transcatheter group (Hazard Ratio [HR]: 0.99, 95%
conﬁdence interval [CI], 0.72-1.35; p¼0.936). Similarly, there were no signiﬁcant
differences in the rates of MACCE between the two groups, which were 17.6% in the
surgical group as compared with 18.2% in the transcatheter group (HR: 1.03, 95%CI
0.78-1.36; p¼0.831). The cumulative incidence of cerebrovascular events, re-hospi-
talization due to cardiac reasons and due to acute heart failure, as assessed by
competing risk regression approach, was similar in both groups at 1 year.
CONCLUSION The results of this study on a large propensity-matched cohort of pa-
tients with severe AS and at intermediate surgical risk show that SAVR and trans-
femoral TAVR have comparable mortality, MACCE, and re-hospitalization due to
cardiac reasons rates at 1 year. These data need to be conﬁrmed at longer terms and by
dedicated ongoing randomized trials.
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BACKGROUND Transcatheter aortic valve replacement (TAVR) is the recommended
therapy for patients with severe calciﬁc aortic stenosis (AS) who are not suitable
candidates for surgery. The aim of this study is to evaluate the quality of life (QoL) for
patients with severe AS with extreme and high surgical risk following TAVR with the
CoreValve Medtronic prosthesis.
METHODS A retrospective analysis of patients who went underwent TAVR was con-
ducted between April 2011, and March 2014. Demographic and clinical data were
obtained from inpatient and outpatient clinical records. QoL assessment was realized
with the SF-12 Health-Survey, a simple questionnaire designed for self-administration
that provides easily interpretable scales for physical [physical component summary
(PCS)] and mental [mental component summary (MCS)] health. The questionnaire
was administered at baseline and 6 months after TAVR.
RESULTS A total of 73 patients underwent TAVR therapy. Of these, 40 patients
successfully completed the SF-12 questionnaire until 6months followup.Mean agewas
85 8.5 years and 61%weremale. A total of 80% of the patients had an improvement in
New York Heart Association (NYHA) class after 6months. Therewas an improvement in
echocardiographic parameters (mean gradient from 48.6  11.1 to 7.9  3.0; p < 0.001
and aortic valve area from0.620.18 to 1.610.37; p<0.001).Mean pre-operative SF12
scores showed a lower perceived quality of life compared with general United States
population >75 years, both for physical (PCS-baseline 30.2 vs. 39.0) and mental scores
(MCS-baseline 46.2 vs. 50.0). After 6 months, a signiﬁcant improvement in both scores
(PCS 37.2; p ¼ 0.002 and MCS 53.2 p ¼ 0.003) was observed.
CONCLUSIONS The main ﬁnding of this study is that TAVR in patients with severe AS
is followed by early improvements in quality of life. The Results: show a marked
improvement in functional status and a signiﬁcant improvement in quality of life in
both physical and mental components
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INTRODUCTION Public demand for Transcatheter Aortic Valve Replacement (TAVR)
2.5 years post approval continues to be strong. However institutions are still
perplexed on how to decrease cost and improve efﬁciency. This discussion addresses
these challenges with the TAVR population and methods which may increase pro-
ductivity while reducing overhead.





















TMETHODS A retrospective review of a single site’s experience with AVR was done. We
looked at documentation/coding, post-operative admissions and the impact of the
transfer penalty. From 11/2007 through 7/2012, 110 patients were coded with major
complications of co-morbidities (220). We then looked at patients admitted to the
post anesthesia unit (PACU) compared to the intensive care unit (ICU). 25 patients
from 6/2013 through 12/2013 met protocol criteria and were admitted to the PACU and
62 to the ICU. We also analyzed the impact of the transfer policy of a sampling of 20
patients.
RESULTS The documentation review of the 110 patients coded with 220 revealed that
59(53%) had evidence which supported acute on chronic heart failure and may have
been eligible for a major complication or co-morbidities (219) diagnosis related group
(DRG). The post-operative admission demonstrated 25 patients admitted to the PACU
with an average length of stay (LOS) 4.42(4.46) days and the 62 patients admitted to
the ICU average LOS was 8.38(6.54) days. 38% of the PACU patients were coded with
219 and 33% with 220. The difference in weighed DRG is 2.6274units. The patients
who were discharge where the transfer penalty applied had a greater than $2000.00
loss per procedure.
CONCLUSION Advancement in healthcare comes with a price. In today’s healthcare
economy institutions continue to balance cost with being able to ofﬁce the community
the latest technology and treatment. This discussion suggests that there is cost saving
opportunities however more research is needed to truly understand the impact.
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OBJECTIVE Transcatheter Aortic Valve Replacement (TAVR) has emerged as an
alternative to high-risk surgery in patients with comorbid conditions. The role of
TAVR in patients with liver disease has not been fully examined.
METHODS We examined the procedural and intermediate to long-term follow-up
outcomes of patients at our institution with aortic valve stenosis and chronic liver
disease, identiﬁed by liver biopsy or from a combination of clinical ﬁndings. All pa-
tients were treated with Sapien or Sapien XT (Edwards Life Sciences, Irvine CA)
balloon-expandable transcatheter bioprosthesis between Nov 2007 and Feb 2014.
RESULTS A total of 17 of 706 (2.41%) patients treated with transfemoral (TF) [n¼14] or
transapical (TA) [n¼3] TAVR had liver disease (mean age 77.79.1 years, 10 men, mean
STS score 8.4, mean MELD score 11.4, Child-Turcotte-Pugh (CTP) Class A [n¼11], B
[n¼6], C [n¼0]). Median follow-up was 466 days (range ¼ 12-1403 days). In-hospital
mortality was 5.88% and 90-day mortality was 17.65%. Safety and efﬁcacy endpoints
as deﬁned by the Valve Academic Research Consortium (VARC) were signiﬁcant for
one perioperative death from a proximate cardiac cause (post-op day 14), one death
after hospital discharge of unknown cause (post-op day 12), two deaths from non-
cardiac causes (post-op days 50 and 487), and one death of unknown cause (post-op
day 1005). There were no life-threatening or major bleeding complications. One pa-
tient had a myocardial infarction, one had a transient ischemic attack, and ﬁve had
transient acute kidney injury.
CONCLUSION TF and TA TAVR are feasible methods in treating aortic stenosis in
patients with liver disease. In patients with mild to moderate liver disease there are
acceptable early and late complications, however, outcomes in patients with
advanced liver disease (MELD > 20 or CTP class C) warrants further study.
Figure 1. Kaplan-Meier Curve of Survival after TAVR
Long term survival of patients with chronic liver disease after TAVR. *Only 2
patients had follow up beyond 1000 days.CRT-804
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BACKGROUND Studies investigating the impact of procedural access on outcome of
severe aortic stenosis (AS) patients undergoing transcatheter aortic valve replace-
ment (TAVR) have shown conﬂicting results. Our aim was to characterize baseline
differences between TAVR patients undergoing via transfemoral (TF) and transapical
(TA) approaches, evaluate the risk for peri-procedural complications, and assess the
impact of access type on early and late mortality.
METHODS Severe AS patients undergoing TAVR at our institution between May 2007
and July 2014 were included. Baseline demographic, clinical and imaging parameters
were compared between TA and TF patients, peri-procedural complications rate were
assessed as well as early and late mortality rates.
RESULTS Among 548 severe AS patients undergoing TAVR, TF approach was used in
428 and TA in 120. Main differences between the 2 groups consisted from lower BMI
in the TA group along with a higher rate of peripheral vascular disease in comparison
with the TF patients. Procedural data indicates shorter ﬂuoroscopy time and smaller
contrast volume in the TA group.
Complications rate were signiﬁcantly higher in the TA group compared with TF
group, with higher AKI rates (18% vs. 5%, p<0.001), major bleeding (15% vs. 6%,
p¼0.002), pleural effusion (23% vs. 4%, p<0.001) and atrial ﬁbrillation (31% vs.
9%, p¼0.004). In addition, an increased mortality rate at 30 days was noticed among
the TA groups in comparison with TF patients (18% vs. 6%, p<0.001). However,
mortality beyond 30 days revealed was similar among both groups (16% vs. 15%,
p¼0.73).
CONCLUSION TA approach TAVR portends increased risk for serious peri-procedural
complications when compared with TF patients. TA patients have higher early mor-
tality in comparison with TF patients; however, mortality rate is similar among pa-
tients surviving the procedure.CRT-805
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BACKGROUND Transcatheter aortic valve implantation (TAVI) is the contemporary
treatment of choice for high/prohibitive surgical risk patients with severe symp-
tomatic aortic stenosis.
METHODS Outcomes of consecutive 275 (61% female) severe aortic stenosis patients,
treated with TAVI and followed up to 3 years (mean 702 days), were analyzed and
reported according to the Valve Academic Research Consortium 2 deﬁnitions. The
primary end point was death from any cause.
RESULTS This patient group (60% women) was characterized by advanced age (mean
81.76.8), high mean logistic EuroScore ¼ 19.112 and STS score ¼ 8.15. The
